# US 2008/0188428 A1 · Bioinformatically detectable group of novel hiv regulatory genes and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188428 A1
- Document ID: US20080188428A1
- Status: Published application
- Kind: A1
- Application number: 10/605,838
- Filed: 2003-10-30
- Published: 2008-08-07
- Earliest claimed: 2002-09-17
- Assignees: Rosetta Genomics Ltd.
- Inventors: Itzhak Bentwich
- Web page: https://patentgrep.com/patent/US20080188428A1

## CPC

- C12N 15/1132: {against retroviridae, e.g. HIV}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C07K 14/005: from viruses
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/1131: {against viruses}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2330/10: naturally occurring
- C12N 2740/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “viral genomic record” or “VGR genes”. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. VGR genes encode an operon-like cluster of VGAM genes. VGAM and viral VGR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.

## Claims

### Claim 1

A bioinformatically detectable novel viral gene encoding substantially pure nucleic acid wherein:
RNA encoded by said bioinformatically detectable novel viral gene is about 18 to about 24 nucleotides in length, and originates from an RNA precursor, which RNA pre-cursor is about 50 to about 120 nucleotides in length;
a nucleotide sequence of a first half of said RNA precursor is a partial inversed-reversed sequence of a nucleotide sequence of a second half thereof;
a nucleotide sequence of said RNA encoded by said novel viral gene is a partial inversed-reversed sequence of a nucleotide sequence of a binding site associated with at least one host target gene; and
a function of said novel viral gene is bioinformatically deducible.

### Claim 2

A bioinformatically detectable novel viral gene encoding substantially pure DNA wherein:
RNA encoded by said bioinformatically detectable novel viral gene comprises a plurality of RNA sections, each of said RNA sections being about 50 to about 120 nucleotides in length, and comprising an RNA segment, which RNA segment is about 18 to about 24 nucleotides in length;
a nucleotide sequence of a first half of each of said RNA sections encoded by said novel gene is a partial inversed-reversed sequence of nucleotide sequence of a second half thereof;
a nucleotide sequence of each of said RNA segments encoded by said novel gene is a partial inversed-reversed sequence of the nucleotide sequence of a binding site associated with at least one target gene; and
a function of said novel gene is bioinformatically deducible from the following data elements: said nucleotide sequence of said RNA encoded by said novel gene, a nucleotide sequence of said at least one target gene, and function of said at least one target gene.

### Claim 3

A bioinformatically detectable novel viral gene encoding substantially pure DNA wherein:
RNA encoded by said bioinformatically detectable novel gene is about 18 to about 24 nucleotides in length, and originates from an RNA precursor, which RNA precursor is about 50 to about 120 nucleotides in length;
a nucleotide sequence of a first half of said RNA precursor is a partial inversed-reversed sequence of a nucleotide sequence of a second half thereof;
a nucleotide sequence of said RNA encoded by said novel gene is a partial inversed-reversed sequence of a nucleotide sequence of a binding site associated with at least one target gene;
a function of said novel gene is modulation of expression of said at least one target gene; and
said at least one target gene does not encode a protein.

### Claim 4 (depends on 1)

A bioinformatically detectable novel gene according to claim 1 and wherein said function of said novel gene is bioinformatically deducible from the following data elements:
said nucleotide sequence of said RNA encoded by said bioinformatically detectable novel gene,
a nucleotide sequence of said at least one target gene; and
a function of said at least one target gene.

### Claim 5 (depends on 1)

A bioinformatically detectable novel gene according to claim 1 and wherein said RNA encoded by said novel gene complementarily binds said binding site associated with said at least one target gene, thereby modulating expression of said at least one target gene.

### Claim 6 (depends on 1)

A bioinformatically detectable novel gene according to claim 1 and wherein:
said binding site associated with at least one target gene is located in an untranslated region of RNA encoded by said at least one target gene.

### Claim 7 (depends on 5)

A bioinformatically detectable novel gene according to claim 5 and wherein:
said function of said novel gene is selective inhibition of translation of said at least one target gene, which selective inhibition comprises complementary hybridization of said RNA encoded by said novel gene to said binding site.

### Claim 8 (depends on 1)

A vector comprising the DNA of claim 1.

### Claim 9 (depends on 8)

A method of selectively inhibiting translation of at least one gene, comprising introducing the vector of claim 8 into a cell.

### Claim 10 (depends on 9)

A method according to claim 9 and wherein said introducing comprises utilizing RNAi pathway.

### Claim 11 (depends on 8, 10)

A gene expression inhibition system comprising:
the vector of claim 8; and
a vector inserter, functional to insert said vector of claim 10 into a cell, thereby selectively inhibiting translation of at least one gene.

### Claim 12 (depends on 1)

A probe comprising the DNA of claim 1.

### Claim 13 (depends on 12)

A method of selectively detecting expression of at least one gene, comprising using the probe of claim 12 (14).

### Claim 14 (depends on 12)

A gene expression detection system comprising:
the probe of claim 12; and
a gene expression detector functional to selectively detect expression of at least one gene.

### Claim 15 (depends on 1)

An anti-viral substance capable of neutralizing said RNA of claim 1.

### Claim 16 (depends on 15)

A substance according to claim 15 and wherein said neutralizing comprises complementarily binding said RNA.

### Claim 17 (depends on 15)

A substance according to claim 15 and wherein said neutralizing comprises immunologically neutralizing.

### Claim 18 (depends on 1)

A method for anti-viral treatment comprising neutralizing said RNA of claim 1.

### Claim 19 (depends on 18)

A method according to claim 18 and wherein said neutralizing comprises:
synthesizing a complementary nucleic acid molecule, a nucleic sequence of which complementary nucleic acid molecule is a partial inversed-reversed sequence of said RNA; and
transfecting host cells with said complementary nucleic acid molecule, thereby complementarily binding said RNA.

### Claim 20 (depends on 18)

A method according to claim 18 and wherein said neutralizing comprises immunologically neutralizing.
